![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Meiji Seika Kaisha Ltd Tokyo Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Colistin sulfate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 1998-091 - Rev 00
This Chemical Type CEP, issued on November 23, 2007, remains in force until April 15, 2011, ensuring its reliability within the pharmaceutical industry.
Substance Number 320 associated with this CEP further emphasizes